The following articles have showcased Absynth Biologics (please note that we are not responsible for the content of external websites).
- Absynth receives £100,000 funding from Yorkshire Forward. December 2008. For more information see Absynth News.
- BBSRC Leaflet. Jan 2008. Issue: Tackling ‘Superbugs’. New companies take up the fight. Absynth Biologics. p. 14. “… a unique group of surface-exposed proteins of S. aureus … are good novel targets for a vaccine and for prophylactic or therapeutic antibodies control of infection … The research findings are being taken towards clinical application by ABsynth Biologics.”
- BBSRC business. Jul 2007. Spin out sets to tackle MRSA. p. 12. “Through underpinning BBSRC-funded research we have identified a unique pool of immunological targets, with esential roles in cellular physiology and pathogenicity … Absynth Biologics gives an exciting opportunity to translate our basic research into real clinical application”
Get a copy at: BBSRC Business
- Helix - Bioscience cluster news from Yorkshire Forward. May 2007. Issue 07. ABsynth Biologics: Spin out company battles superbug. p. 2. “The concept (Absynth Biologics) uses an immunological approach to target a novel set of proteins ... important for the growth and/or pathogenesis of the bacterium …”